OOIR: Observatory of International Research

Papers

(The TQCC of Medicinal Research Reviews is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Mechanisms of neuronal cell death in ischemic stroke and their therapeutic implications	234
The role of hypoxia‐inducible factor 1 in tumor immune evasion	156
Evolution of the adaptogenic concept from traditional use to medical systems: Pharmacology of stress‐ and aging‐related diseases	148
Chemical molecular‐based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp)	148
Molecular targeting therapies for neuroblastoma: Progress and challenges	142
Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: Where are we today?	135
Mitochondria and lipid peroxidation in the mechanism of neurodegeneration: Finding ways for prevention	133
Understanding the tumor microenvironment for effective immunotherapy	128
Artificial intelligence and machine learning‐aided drug discovery in central nervous system diseases: State‐of‐the‐arts and future directions	115
Mechanisms of melanocyte death in vitiligo	107
Small molecules regulating reactive oxygen species homeostasis for cancer therapy	105
Biologically active isoquinoline alkaloids covering 2014–2018	105
A review in radiomics: Making personalized medicine a reality via routine imaging	103
Tripterygium wilfordii: An inspiring resource for rheumatoid arthritis treatment	100
From combinations to multitarget‐directed ligands: A continuum in Alzheimer's disease polypharmacology	81
Therapeutic potential of phenylethanoid glycosides: A systematic review	79
Chalcone hybrids as potential anticancer agents: Current development, mechanism of action, and structure‐activity relationship	79
Phytochemistry and cardiovascular protective effects of Huang‐Qi (Astragali Radix)	78
Flavonoids as antiobesity agents: A review	78
Antimicrobial peptides, conventional antibiotics, and their synergistic utility for the treatment of drug‐resistant infections	76
The immunosuppressive activity of artemisinin‐type drugs towards inflammatory and autoimmune diseases	76
Emerging carrier‐free nanosystems based on molecular self‐assembly of pure drugs for cancer therapy	73
What coronavirus 3C‐like protease tells us: From structure, substrate selectivity, to inhibitor design	71
Emerging roles of SIRT6 in human diseases and its modulators	71
Emerging use of senolytics and senomorphics against aging and chronic diseases	70

Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases	69
Autophagy and cardiac diseases: Therapeutic potential of natural products	68
Metabolites of microbiota response to tryptophan and intestinal mucosal immunity: A therapeutic target to control intestinal inflammation	67
Skp2 in the ubiquitin‐proteasome system: A comprehensive review	64
Bioactive polymeric scaffolds for osteogenic repair and bone regenerative medicine	63
The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy	62
COVID‐19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays	61
Direct targeting of β‐catenin in the Wnt signaling pathway: Current progress and perspectives	58
Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing	57
Reinvigorating exhausted CD8⁺ cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy	56
Pharmaceuticals targeting signaling pathways of endometriosis as potential new medical treatment: A review	54
Mitochondrial dysfunction in cardiovascular disease: Current status of translational research/clinical and therapeutic implications	51
Development of anti‐influenza agents from natural products	49
Biologically active indolizidine alkaloids	47
Glycogen synthesis and beyond, a comprehensive review of GSK3 as a key regulator of metabolic pathways and a therapeutic target for treating metabolic diseases	47
Strategies for designing proteolysis targeting chimaeras (PROTACs)	46
KEAP1‐NRF2 protein–protein interaction inhibitors: Design, pharmacological properties and therapeutic potential	46
Structure and therapeutic uses of butyrylcholinesterase: Application in detoxification, Alzheimer's disease, and fat metabolism	46
The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases	44
Haste makes waste: A critical review of docking‐based virtual screening in drug repurposing for SARS‐CoV‐2 main protease (M‐pro) inhibition	44
Biosynthesis, total synthesis, structural modifications, bioactivity, and mechanism of action of the quinone‐methide triterpenoid celastrol	40
Activation of transcription factor Nrf2 to counteract mitochondrial dysfunction in Parkinson's disease	40
Cistanches Herba, from an endangered species to a big brand of Chinese medicine	40
Cardiac efficacy and toxicity of aconitine: A new frontier for the ancient poison	40
Extracellular vesicles: Emerging frontiers in wound healing	40
Trends in targeted delivery of nanomaterials in colon cancer diagnosis and treatment	39
A novel strategy for the diagnosis, prognosis, treatment, and chemoresistance of hepatocellular carcinoma: DNA methylation	39
Protein corona formed in the gastrointestinal tract and its impacts on oral delivery of nanoparticles	39
Recent progress and new perspectives for diterpenoid biosynthesis in medicinal plants	39
Harnessing hyperuricemia to atherosclerosis and understanding its mechanistic dependence	38
Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities	38
Anti‐VEGF DNA‐based aptamers in cancer therapeutics and diagnostics	38
Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: Helping to fight against cancer via multiple targets	37
Metabolomics as a tool for the early diagnosis and prognosis of diabetic kidney disease	37
Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use	37
Targeting telomerase for its advent in cancer therapeutics	37
The Yin and Yang of traditional Chinese and Western medicine	35
Pattern recognition receptor‐mediated inflammation in diabetic vascular complications	35
Making smart drugs smarter: The importance of linker chemistry in targeted drug delivery	35
New‐generation, non‐SSRI antidepressants: Drug‐drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and others	35
Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer	34
Mechanism of epithelial‐mesenchymal transition in cancer and its regulation by natural compounds	34
Expedition of sulfur‐containing heterocyclic derivatives as cytotoxic agents in medicinal chemistry: A decade update	34
Association predictions of genomics, proteinomics, transcriptomics, microbiome, metabolomics, pathomics, radiomics, drug, symptoms, environment factor, and disease networks: A comprehensive approach	34
SARS‐CoV‐2‐mediated immune system activation and potential application in immunotherapy	34
Photodynamic therapy: Innovative approaches for antibacterial and anticancer treatments	33
Drug design targeting active posttranslational modification protein isoforms	33
The role and therapeutic potential of Hsp90, Hsp70, and smaller heat shock proteins in peripheral and central neuropathies	32
Salinomycin as a potent anticancer stem cell agent: State of the art and future directions	32
Pipeline of anti‐Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities	32

The role of carbon monoxide, heme oxygenase 1, and the Nrf2 transcription factor in the modulation of chronic pain and their interactions with opioids and cannabinoids	32
Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness	32
Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson's disease in the precision medicine era	31
Targeting the HSP90–CDC37–kinase chaperone cycle: A promising therapeutic strategy for cancer	31
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective	30
NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications	28
An eye on the dog as the scientist's best friend for translational research in ophthalmology: Focus on the ocular surface	27
Systematic review of pharmacokinetics and potential pharmacokinetic interactions of flavonolignans from silymarin	27
Adipose‐derived stromal cells for nonhealing wounds: Emerging opportunities and challenges	27
Dual‐target inhibitors of bromodomain and extra‐terminal proteins in cancer: A review from medicinal chemistry perspectives	27
Noncoding RNAs as regulators of STAT3 pathway in gastrointestinal cancers: Roles in cancer progression and therapeutic response	26
The role of long noncoding RNA in lipid, cholesterol, and glucose metabolism and treatment of obesity syndrome	26
Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors	26
A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy	25
Inflammatory bowel disease biomarkers	25
Drug repurposing approach to combating coronavirus: Potential drugs and drug targets	25
The role of FOXOs and autophagy in cancer and metastasis—Implications in therapeutic development	25
Druggability modification strategies of the diarylpyrimidine‐type non‐nucleoside reverse transcriptase inhibitors	24
(Nano)platforms in breast cancer therapy: Drug/gene delivery, advanced nanocarriers and immunotherapy	24
Mitochondria as a promising target for developing novel agents for treating Alzheimer's disease	24
Microglia‐derived galectin‐3 in neuroinflammation; a bittersweet ligand?	24
Heat shock protein 60 and cardiovascular diseases: An intricate love‐hate story	24
Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR‐targeting agents to treat head and neck squamous cell carcinoma	24